You are here: Industry Insights > boehringer

News List

BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim b3cnewswire
January 16, 2020
BioMed X announced the start of a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg.
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint pharmaceutical-business-review
December 20, 2019
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
Boehringer partners with Healx for AI-based drug discovery pharmaceutical-technology
December 11, 2019
German pharmaceutical company Boehringer Ingelheim has partnered with UK-based drug technology firm Healx to identify approaches to treat rare neurological disorders.
Boehringer and Inflammasome to develop retinal therapies pharmaceutical-technology
September 24, 2019
The alliance will leverage Inflammasome’s intravitreal (IVT) drug delivery technologies to develop compounds in Boehringer’s retinal disease pipeline portfolio.
FDA Approves Boehringer’s Ofev contractpharma
September 10, 2019
Becomes the first and only therapy to slow the rate of decline in pulmonary function in systemic sclerosis-associated ILD.
Boehringer partners with MD Anderson on virtual R&D centre pharmaceutical-technology
August 15, 2019
Boehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research.
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies worldpharmanews
August 14, 2019
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers,
Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center contractpharma
August 13, 2019
New potential gastrointestinal and lung cancer therapies from Boehringer’s pipeline will be combined with MD’s drug development capabilities.
Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline contractpharma
July 24, 2019
Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877.
Boehringer forms alliance with Bridge Biotherapeutics for IPF drug pharmaceutical-technology
July 22, 2019
Boehringer Ingelheim has entered a collaboration and licence agreement to develop South Korea-based Bridge Biotherapeutics’ drug candidate for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).

Previous page 1 2 3 4 5 6 Next page